$2.44
-0.26 (-9.63%)
Open$2.72
Previous Close$2.70
Day High$2.77
Day Low$2.44
52W High$5.33
52W Low$1.36
Volume—
Avg Volume198.2K
Market Cap125.72M
P/E Ratio—
EPS$-1.02
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+688.5% upside
Current
$2.44
$2.44
Target
$19.24
$19.24
$16.83
$19.24 avg
$29.48
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 100.41M | 70.32M | 27.35M |
| Net Income | -31,197,988 | -19,663,974 | 6.20M |
| Profit Margin | -31.1% | -29.5% | 22.7% |
| EBITDA | -8,577,118 | -5,706,465 | 9.44M |
| Free Cash Flow | — | — | 4.10M |
| Rev Growth | +42.8% | +42.8% | -0.5% |
| Debt/Equity | 4.00 | 4.00 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |